A Mechanistic Study of the Feasibility of Ursodeoxycholic Acid in the Treatment of Colon Adenocarcinoma

被引:0
|
作者
Liu, Shuyu [1 ,2 ]
Zhou, Mengyue [3 ]
Huang, Xiaoli [2 ]
Chen, Peng [2 ]
Li, Quanpeng [1 ]
Wang, Yuting [1 ]
Ge, Xianxiu [1 ]
Wang, Fei [1 ]
Xu, Jianing [1 ]
Gu, Jiayi [4 ]
Miao, Lin [1 ]
Deng, Xueting [1 ]
机构
[1] Nanjing Med Univ, Med Ctr Digest Dis, Affiliated Hosp 2, 121 Jiangjiayuan, Nanjing 210011, Jiangsu, Peoples R China
[2] Nanjing Med Univ, Affiliated Hosp 4, Dept Gastroenterol, Nanjing, Peoples R China
[3] Nanjing Pukou Hosp Tradit Chinese Med, Dept Gastroenterol, Nanjing, Peoples R China
[4] Nanjing Med Univ, Affiliated Hosp 4, Dept Neurol, Nanjing, Peoples R China
来源
关键词
ursodeoxycholic acid; colon adenocarcinoma treatment; bile acid metabolism; cell death; CELLS;
D O I
10.2147/DDDT.S500721
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Purpose: Bile acids promote the progression of colon adenocarcinoma (COAD), and ursodeoxycholic acid (UDCA) is a key drug in promoting bile acid excretion, but its role in COAD unclear. Our study aims to investigate the relationship between COAD and bile acid metabolism and to assess the feasibility of UDCA for the treatment of COAD. Methods: Firstly, biological targets closely related to COAD were identified: Based on the cancer genome atlas (TCGA) database, the core genes of COAD were obtained by differential expression analysis and weighted gene-coexpression network analysis (WGCNA), and subjected to gene ontology (GO) function annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. Secondly, finding a drug by target, after identifying UDCA as a candidate drug, the feasibility of UDCA in treating COAD was verified in reverse: Using databases to collect potential targets for COAD and UDCA, and the intersecting genes were the potential targets for UDCA to exert anti-tumor effects. Then Autodock was used for molecular docking to analyze the interaction between UDCA and core target proteins. Finally, experimental validation was performed: MTT assay, wound healing, transwell migration, and angiogenesis assays were used to detect the effects of UDCA on cell proliferation, migration, invasion, and neovascularization. Results: 2064 differential genes were screened from TCGA. WGCNA obtained the module most relevant to CRC, containing 493 genes. KEGG analysis found that overlapping genes were mainly concentrated in bile acid metabolic pathways. A total of 26 UDCA anti-tumor targets were obtained in database, and 5 core targets were selected by STRING database and Cytoscape software: TNF, CYP27B1, MDM2, MMP2, CASP3. Molecular docking results showed that UDCA had good binding activity with the core targets. In vitro experiment showed UDCA effectively inhibited the proliferation, migration, invasion and neovascularization in colon cancer cells. Conclusion: The antitumor activity of ursodeoxycholic acid may be related to cell apoptosis, proliferation, migration and vascular neogenesis.
引用
收藏
页码:1839 / 1852
页数:14
相关论文
共 50 条
  • [41] Ursodeoxycholic acid treatment for primary sclerosing cholangitis
    Mol, Bregje
    van Munster, Kim
    Weersma, Rinse
    Inderson, Akin
    Boonstra, Kirsten
    Drenth, Joost P. H.
    van Meer, Suzanne
    de Vries, Elsemieke S.
    Spanier, B. W. Marcel
    Vrij, Ton
    Verlaan, Tess
    van Duijn, Femke
    Ponsioen, Willemijn
    Beuers, Ulrich
    Dijkgraaf, Marcel
    Ponsioen, Cyriel
    JOURNAL OF HEPATOLOGY, 2024, 80 : S317 - S317
  • [42] Ursodeoxycholic acid in the treatment of intraheptic cholestasis of pregnancy
    Liu Yuling
    Qiao Fuyuan
    Liu Haiyi
    Liu Dayan
    Journal of Huazhong University of Science and Technology [Medical Sciences], 2006, 26 (3): : 350 - 352
  • [43] URSODEOXYCHOLIC ACID THERAPY IN THE TREATMENT OF BILIARY ATRESIA
    NITTONO, H
    TOKITA, A
    HAYASHI, M
    WATANABE, T
    OBINATA, K
    NAKATSU, N
    MIYANO, T
    BIOMEDICINE & PHARMACOTHERAPY, 1989, 43 (01) : 37 - 41
  • [44] Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis
    Stiehl, A
    ITALIAN JOURNAL OF GASTROENTEROLOGY, 1996, 28 (03): : 178 - 180
  • [45] URSODEOXYCHOLIC ACID - A POSSIBLE TREATMENT FOR SCLEROSING CHOLANGITIS
    CHAZOUILLERES, O
    POUPON, R
    CAPRON, JP
    METMAN, EH
    DHUMEAUX, D
    AMOURETTI, M
    COUZIGOU, P
    LABAYLE, D
    TRINCHET, JC
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 1989, 13 (2BIS): : A2 - A2
  • [46] Pharmacological treatment of biliary cirrhosis with ursodeoxycholic acid
    Abbas, Ghulam
    Lindor, Keith D.
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (03) : 387 - 392
  • [47] TREATMENT OF CHOLESTEROL GALLSTONE PATIENTS WITH URSODEOXYCHOLIC ACID
    MARZIO, L
    GASTROENTEROLOGY, 1991, 101 (01) : 275 - 276
  • [48] Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis
    Stiehl, A
    BILE ACIDS AND IMMUNOLOGY, 1996, 86 : 248 - 250
  • [49] Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis
    Kiyici, M
    Gulten, M
    Gurel, S
    Nak, SG
    Dolar, E
    Savci, G
    Adim, SB
    Yerci, O
    Memik, F
    CANADIAN JOURNAL OF GASTROENTEROLOGY, 2003, 17 (12): : 713 - 718
  • [50] Ursodeoxycholic acid for the treatment of hepatic sarcoid: A pre-post pilot study
    Weinberg, Ethan
    Stonelake, Aimee
    Borges, Kelly
    Toal, Emily
    Aghayeva, Sevda
    Rossman, Milton
    Ligon, Colin
    Reddy, K. Rajender
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2024, 10 (03) : 194 - 196